GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

The Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) and Informing the Pathway of Chronic ...

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA). Jeffrey D.

Implications for treating chronic obstructive pulmonary disease with combination regimens based on clinical data and how the condition will likely be managed in the coming years. Transcript Neil B.

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...

Effective treatment often requires you to take medications to better manage symptoms or stop taking medications if a doctor advises that you no longer need them. Finding the right dosages and ...

Select your location to view local American Lung Association events and news near you.